Next Article in Journal
Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic
Previous Article in Journal
Clinicopathological Significances of Tumor–Stroma Ratio (TSR) in Colorectal Cancers: Prognostic Implication of TSR Compared to Hypoxia-Inducible Factor-1α Expression and Microvessel Density
Open AccessArticle

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

1
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150040, China
2
Radiology Department, Harbin Medical University Cancer Hospital, Harbin 150040, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work as co-first authors.
Curr. Oncol. 2021, 28(2), 1325-1337; https://doi.org/10.3390/curroncol28020126
Received: 13 January 2021 / Revised: 14 March 2021 / Accepted: 19 March 2021 / Published: 23 March 2021
Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity and other adverse outcomes. Methods: We retrospectively analyzed 201 DLBCL patients who underwent pre-treatment abdominal CT examination. CT images were used to assess body composition metrics at the third lumbar vertebrae including fat tissues and muscle. Based on the skeletal muscle area (SMA) and density (SMD), skeletal muscle index (SMI), skeletal muscle gauge (SMG = SMI × SMD) and lean body mass (LBM) were calculated. Also analyzed were the toxicity, adverse events and survival. Results: We found that SMG, SMD, SMI and LBM were correlated with any grade 3–4 toxicity, dose reduction, hospitalization or termination of the treatment due to immunochemotherapy and worse survival. However, multivariate analysis demonstrated SMG [progression-free survival (PFS): hazard ratio (HR), 2.889; 95% CI, 1.401–5.959; p = 0.004; overall survival (OS): HR, 2.655; 95% CI, 1.218–5.787; p = 0.014] was the best predictor of poor prognosis. Conclusions: SMG, SMD, SMI and LBM were identified as predictors of adverse reactions and poor survival. SMG was an innovative and valuable indicator of immunochemotherapy toxicity and other adverse outcomes. Additionally, it can be used to individualize antineoplastic drug dosing. View Full-Text
Keywords: diffuse large B-cell lymphoma; immunochemotherapy; survival; sarcopenia; toxicity diffuse large B-cell lymphoma; immunochemotherapy; survival; sarcopenia; toxicity
Show Figures

Figure 1

MDPI and ACS Style

Guo, J.; Cai, P.; Li, P.; Cao, C.; Zhou, J.; Dong, L.; Yang, Y.; Xuan, Q.; Wang, J.; Zhang, Q. Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy. Curr. Oncol. 2021, 28, 1325-1337. https://doi.org/10.3390/curroncol28020126

AMA Style

Guo J, Cai P, Li P, Cao C, Zhou J, Dong L, Yang Y, Xuan Q, Wang J, Zhang Q. Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy. Current Oncology. 2021; 28(2):1325-1337. https://doi.org/10.3390/curroncol28020126

Chicago/Turabian Style

Guo, Jiaxun; Cai, Panpan; Li, Pengfei; Cao, Cong; Zhou, Jing; Dong, Lina; Yang, Yan; Xuan, Qijia; Wang, Jingxuan; Zhang, Qingyuan. 2021. "Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy" Curr. Oncol. 28, no. 2: 1325-1337. https://doi.org/10.3390/curroncol28020126

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop